(S)-Furaltadone hydrochloride | 13146-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: (S)-Furaltadone hydrochloride
• 英文别名: (5S)-5-(morpholin-4-ylmethyl)-3-[(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one;hydrochloride
• CAS: 13146-28-6
• 化学式: C13H17ClN4O6
• 分子量: 360.75
• InChiKey: PPSVFZXMDMUIGB-MERQFXBCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• IDENTIFICATION OF STRUCTURALLY SIMILAR SMALL MOLECULES THAT ENHANCE THERAPEUTIC EXON SKIPPING
  申请人：The Regents of the University of California

  公开号：US20160257952A1

  公开（公告）日：2016-09-08

  This invention relates, e.g., to a method for enhancing exon skipping in a pre-mRNA of interest, comprising contacting the pre-mRNA with an effective amount of a compound such as, for example, Perphenazine, Flupentixol DiHCl, Zuclopenthixol or Corynanthine HCl, or a compound which shares a similar 2-D structure and activity level with one of these compounds, or a pharmaceutically acceptable salt, hydrate, solvate, or isomer of the compound, and, optionally, with an antisense oligonucleotide that is specific for a splicing sequence in the pre-mRNA Methods for treating Duchenne muscular dystrophy (DMD) are disclosed.

  本发明涉及一种增强感兴趣的前mRNA的外显子跳跃的方法，包括将前mRNA与有效量的化合物接触，例如Perphenazine、Flupentixol DiHCl、Zuclopenthixol或Corynanthine HCl，或具有类似2-D结构和活性水平的化合物，或化合物的药学上可接受的盐，水合物，溶剂化物或异构体，以及选择性针对前mRNA中剪接序列的反义寡核苷酸（如果需要）。还公开了治疗杜氏肌肉萎缩症（DMD）的方法。
• An otorhinological drug delivery device
  申请人：Schering Oy

  公开号：EP1438942A1

  公开（公告）日：2004-07-21

  The invention relates to an otorhinological delivery device comprising at least one pharmaceutically active agent. According to the invention the device comprises a core comprising said at least one pharmaceutically active agent wherein said core is made of an elastomer composition selected from the group consisting of poly(dimethylsiloxane), a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units, a siloxane-based elastomer comprising poly(alkylene oxide) groups and mixtures thereof.

  本发明涉及一种包含至少一种药用活性剂的耳鼻喉给药装置。根据本发明，该装置包括一个包含所述至少一种药物活性剂的芯体，其中所述芯体由弹性体组合物制成，该弹性体组合物选自聚（二甲基硅氧烷）、硅氧烷基弹性体（包含连接到硅氧烷单元S原子上的3,3,3-三氟丙基）、硅氧烷基弹性体（包含聚（环氧烷）基团）及其混合物组成的组。
• Methods and compositions for treating infection
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US10004701B2

  公开（公告）日：2018-06-26

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Identification of small molecules that facilitate therapeutic exon skipping
  申请人：The Regents of the University of California

  公开号：US10188633B2

  公开（公告）日：2019-01-29

  This invention relates, e.g., to a method for enhancing exon skipping in a pre-mRNA of interest, comprising contacting the pre-mRNA with an effective amount of a small molecule selected from the compounds shown in Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, and, optionally, with an antisense oligonucleotide that is specific for a splicing sequence in the pre-mRNA Methods for treating Duchenne muscular dystrophy (DMD) are disclosed.

  本发明涉及一种增强相关前mRNA中外显子跳越的方法，该方法包括使前mRNA与有效量的选自表1所示化合物的小分子或其药学上可接受的盐、水合物、溶液或异构体接触，以及与针对前mRNA中剪接序列特异的反义寡核苷酸接触。